This ML-based software solution identifies prediabetic patients at high risk for progressing to Type 2 Diabetes (T2D) within 12 months using only existing, routine blood test results and other parameters such as age, gender, and BMI.
The CDC estimates up to 43 million flu cases (and 61,000 deaths) annually in the US alone. This led EarlySign to develop our newest AlgoMarker, focused on increasing flu vaccination coverage by enabling healthcare systems to strengthen prevention efforts for those populations at highest risk to develop flu-related complications if infected.